翰森制药创新药阿美乐获NMPA受理 拓展肺癌治疗新路径

财中社
27 Nov 2024

财中社11月27日电翰森制药(03692)发布公告,称其创新药阿美乐®(甲磺酸阿美替尼片)的第五项上市许可申请已获中国国家药品监督管理局(NMPA)受理。该药物适应症为与培美曲塞和铂类化疗药物联合使用,针对具有表皮生长因子受体(EGFR)外显子19缺失或外显子21(L858R)置换突变的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者的一线治疗。阿美乐®是中国首个原研的三代EGFR-TKI类...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10